Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Country
- 🇨🇳China
- Ownership
- Joint Venture, Subsidiary
- Established
- 1997-04-16
- Employees
- -
- Market Cap
- -
- Website
- http://www.cttq.com
Study of Methylnaltrexone in Opioid-Induced Constipation Patients
- First Posted Date
- 2015-10-14
- Last Posted Date
- 2015-10-14
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 198
- Registration Number
- NCT02574819
- Locations
- 🇨🇳
Henan Provincial Cancer Hospital, Zhengzhou, Henan, China
🇨🇳The Affiliated Hospital of Xuzhou Medical College, Xuzhou, Jiangsu, China
🇨🇳Xin Hua Hospital affiliated to Shanghai Jiao Tong University School of Medicine Chongming Branch, Shanghai, Shanghai, China
A Study of Sinotecean on Tolerance and Pharmacokinetics
- First Posted Date
- 2015-06-12
- Last Posted Date
- 2015-06-12
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT02469883
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)
- First Posted Date
- 2015-06-03
- Last Posted Date
- 2017-12-29
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 378
- Registration Number
- NCT02461407
- Locations
- 🇨🇳
The First Affiliated Hospital, Anhui Medical University, Hefei, Anhui, China
🇨🇳The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China
🇨🇳Fourth Hospital of Hebei Medical University Tumor Hospital of Hebei Province, Shijiazhuang, Hebei, China
Study of Anlotinib in Patients With Soft Tissue Sarcoma（STS）(ALTER0203)
- First Posted Date
- 2015-05-20
- Last Posted Date
- 2017-04-25
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 233
- Registration Number
- NCT02449343
- Locations
- 🇨🇳
Gansu Cancer Hospital, Lanzhou, Gansu, China
🇨🇳Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳Guangxi medical university affiliated tumor hospital, Nanning, Guangxi, China
Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（ALTER0303）
- First Posted Date
- 2015-03-17
- Last Posted Date
- 2017-09-18
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 439
- Registration Number
- NCT02388919
- Locations
- 🇨🇳
Xinqiao Hospital, Chongqing, Chongqing, China
🇨🇳Gansu Provincial People 's Hospital, Lanzhou, Gansu, China
🇨🇳First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China
Study of Anlotinib in Patients With Metastatic Colorectal Cancer（mCRC）(ALTER0703)
- First Posted Date
- 2015-01-06
- Last Posted Date
- 2019-05-21
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 419
- Registration Number
- NCT02332499
- Locations
- 🇨🇳
The 307th Hospital of Chinese People's Liberation Army, Beijing, Beijing, China
🇨🇳The 1st Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
🇨🇳Chongqing Cancer Hospital, Chongqing, Chongqing, China
Efficacy and Safety of Domestic Tenofovir Tablets in Chinese Patients With Chronic Hepatitis B
- Conditions
- Interventions
- First Posted Date
- 2014-11-11
- Last Posted Date
- 2019-03-19
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 360
- Registration Number
- NCT02287857
- Locations
- 🇨🇳
Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China
🇨🇳First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
🇨🇳Beijing Ditan Hospital Capital Medical University, Beijing, Beijing, China
Efficacy and Safety of L-Pantoprazole Sodium Injection to Treat Upper Gastrointestinal Ulcer Bleeding
- Conditions
- Interventions
- First Posted Date
- 2014-04-09
- Last Posted Date
- 2014-04-09
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 272
- Registration Number
- NCT02108756
- Locations
- 🇨🇳
The first affiliated hospital of the Fourth Military Medical University, Xi'an, Shaanxi, China
Phase II Study of Anlotinib Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma（RCC）
- First Posted Date
- 2014-02-26
- Last Posted Date
- 2016-04-26
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 133
- Registration Number
- NCT02072031
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳Chongqing Cancer Hospital, Chongqing, Chongqing, China
🇨🇳Gansu Province Tumor Hospital, Lanzhou, Gansu, China
Phase II Study of Anlotinib in Patients With Advanced Renal Cell Carcinoma That Have Failed Or Are Intolerant To TKIs Therapy
- First Posted Date
- 2014-02-26
- Last Posted Date
- 2017-12-29
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT02072044
- Locations
- 🇨🇳
Cancer Hospital of Fudan University, Shanghai, Shanghai, China
🇨🇳Chongqing Cancer Hospital, Chongqing, Chongqing, China
🇨🇳Tianjin Medical University Cancer Hospital, Tianjin, Tianjin, China